Global Information
회사소개 | 문의 | 비교리스트

세계의 제한효소 시장 : 예측과 기회(-2025년)

Global Restriction Endonuclease Market By Type, By Application, By End Type, By Source, By Cleavage Specificity, By End-User, By Region, Competition, Forecast & Opportunities, 2025

리서치사 TechSci Research
발행일 2020년 05월 상품 코드 934761
페이지 정보 영문 116 Pages
가격
US $ 4,450 ₩ 5,088,000 Unprintable PDF and Excel (Single User License)
US $ 5,450 ₩ 6,231,000 PDF and Excel (Multi-User License)
US $ 9,450 ₩ 10,805,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 제한효소 시장 : 예측과 기회(-2025년) Global Restriction Endonuclease Market By Type, By Application, By End Type, By Source, By Cleavage Specificity, By End-User, By Region, Competition, Forecast & Opportunities, 2025
발행일 : 2020년 05월 페이지 정보 : 영문 116 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 제한효소 시장은 예측기간 동안 강력한 연평균 복합 성장률(CAGR)로 성장할 전망입니다. 시장 성장 주요인은 생명공학 분야와 제약 업계 등 최종 이용 업계에서의 연구개발 활동에 대한 투자 증가입니다. 또한, 당뇨병, 암 등의 만성 건강장애 발생률 상승은 앞으로 몇 년간 전세계 제한효소 시장 성장의 전조가 될 것으로 예상됩니다.

세계의 제한효소(Restriction Endonuclease) 시장을 부문별/지역별로 조사했으며, 시장 규모 및 시장 점유율 예측, 성장 촉진요인과 과제, 시장 동향, 경쟁 상황, 기업 개요 등의 정보를 전해드립니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 세계 제한효소 시장에 대한 코로나19(COVID-19)의 영향

제4장 개요

제5장 세계의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별(I, II, III, IV)
    • 용도별(유전자공학, DNA 매핑, 유전자 시퀀싱 등)
    • End Type별(Sticky End, Blunt End)
    • 소스별(세균, 고세균)
    • Cleavage Specificity별(Isoschizomers, Neoschizomers)
    • 최종사용자별(제약 및 생명공학 기업, 학술연구기관 등)
    • 기업별(2019년)
    • 지역별
  • 시장 매력 지수

제6장 아시아태평양의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별
    • 용도별
    • End Type별
    • 소스별
    • Cleavage Specificity별
    • 최종사용자별
    • 국가별
  • 시장 매력 지수
  • 아시아태평양 : 국가 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 싱가포르
    • 호주

제7장 유럽의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별
    • 용도별
    • End Type별
    • 소스별
    • Cleavage Specificity별
    • 최종사용자별
    • 국가별
  • 시장 매력 지수
  • 유럽 : 국가 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 북미의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별
    • 용도별
    • End Type별
    • 소스별
    • Cleavage Specificity별
    • 최종사용자별
    • 국가별
  • 시장 매력 지수
  • 북미 : 국가 분석
    • 미국
    • 멕시코
    • 캐나다

제9장 남미의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별
    • 용도별
    • End Type별
    • 소스별
    • Cleavage Specificity별
    • 최종사용자별
    • 국가별
  • 시장 매력 지수
  • 남미 : 국가 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 제한효소 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • Type별
    • 용도별
    • End Type별
    • 소스별
    • Cleavage Specificity별
    • 최종사용자별
    • 국가별
  • 시장 매력 지수
  • 중동 및 아프리카 : 국가 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

제13장 경쟁 상황

  • 경쟁 전망
  • 주요 기업 개요
    • New England Biolabs
    • Thermo Fisher Scientific
    • Takara Bio
    • Sigma-Aldrich
    • Illumina
    • Agilent Technologies
    • Promega
    • Jena Biosciences
    • Genetix Biotech Asia Pvt. Ltd.
    • Roche
    • Merck
    • Pfizer
    • Amgen
    • Vertex Pharmaceuticals
    • BioMarin Pharmaceutical
    • PerkinElmer
    • Abcam
    • Abbexa
    • Sisco Research Laboratories Pvt Ltd
    • Nippon Gene

제14장 전략적 권장사항

제15장 면책 사항

LSH 20.06.05

Global restriction endonuclease market is expected to grow at a formidable CAGR during the forecast period. The key factor responsible for market growth is growing investment in research and development activities in end use industries such as biotechnology sector and pharmaceutical industry. Additionally, rising incidences of chronic health disorders like diabetes, cancer among others is anticipated to bode well for the growth of restriction endonuclease market across the globe in the coming years. Moreover, increasing government support in terms of providing funds is projected to bolster the market growth through 2025.

The global restriction endonuclease market is segmented based on type, application, end type, source, cleavage, end-user, region and company. Based on type, the market can be segmented into Type I, Type II, Type III and Type IV. Out of which, the Type II segment dominated the market in terms of largest market size until 2019 and is further anticipated to maintain its lead during the forecast years as well. This growth can be accredited to its use in molecular biology applications that are carried on everyday such as gene cloning and DNA fragmentation and analysis. Also, because these enzymes cleave DNA at fixed positions, therefore small, well-defined fragments of DNA are produced which assist in characterization of genes and genomes, thereby anticipated to boost the growth of Type II restriction endonucleases segment over the coming years. Moreover, increasing investments in development activities by biotechnology companies is further aiding the segmental growth.

Major players operating in the global restriction endonuclease market include New England Biolabs, Thermo Fisher Scientific, Takara Bio, Sigma-Aldrich, Illumina, Agilent Technologies, Promega, Jena Biosciences, Genetix Biotech Asia Pvt. Ltd., Roche, Merck, Pfizer, Amgen, Vertex Pharmaceuticals, BioMarin Pharmaceutical, PerkinElmer, Abcam, Abbexa, Sisco Research Laboratories Pvt Ltd, Nippon Gene. The companies operating in restriction endonuclease market across the globe are focussing more towards the expanding their share in the market. For instance, these key players are making organic strategies such as developing novel technologies in order to meet the requirements of users and to make the industry highly competitive.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyse and forecast the market size of global restriction endonuclease market.
  • To classify and forecast global restriction endonuclease market based on type, application, end type, source, cleavage, end-user, company and regional distribution.
  • To identify drivers and challenges for global restriction endonuclease market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global restriction endonuclease market.
  • To conduct pricing analysis for global restriction endonuclease market.
  • To identify and analyse the profile of leading players operating in global restriction endonuclease market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global restriction endonuclease market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Restriction endonuclease companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to restriction endonuclease
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global restriction endonuclease market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Type:

Type I

Type II

Type III

Type IV

  • Market, By Application:

Genetic Engineering

DNA Mapping

Gene Sequencing

Others

  • Market, By End Type:

Sticky End

Blunt End

  • Market, By Source:

Bacteria

Archaea

  • Market, By Cleavage Specificity:

Isoschizomers

Neoschizomers

  • Market, By End-User:

Pharmaceutical and Biotechnology Companies

Academic Research Institutes

Others

  • Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore

Middle East and Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global restriction endonuclease market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Restriction Endonuclease Market

4. Executive Summary

5. Global Restriction Endonuclease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (I, II, III, IV)
    • 5.2.2. By Application ( Genetic Engineering, DNA Mapping, Gene Sequencing and Others)
    • 5.2.3. By End Type (Sticky End, Blunt End)
    • 5.2.4. By Source (Bacteria, Archaea)
    • 5.2.5. By Cleavage Specificity (Isoschizomers, Neoschizomers)
    • 5.2.6. By End-User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes and Others)
    • 5.2.7. By Company (2019)
    • 5.2.8. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Restriction Endonuclease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End Type
    • 6.2.4. By Source
    • 6.2.5. By Cleavage Specificity
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Restriction Endonuclease Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Type
        • 6.4.1.2.2. By Application
        • 6.4.1.2.3. By End Type
        • 6.4.1.2.4. By Source
        • 6.4.1.2.5. By Cleavage Specificity
        • 6.4.1.2.6. By End-User
    • 6.4.2. India Restriction Endonuclease Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Type
        • 6.4.2.2.2. By Application
        • 6.4.2.2.3. By End Type
        • 6.4.2.2.4. By Source
        • 6.4.2.2.5. By Cleavage Specificity
        • 6.4.2.2.6. By End-User
    • 6.4.3. Japan Restriction Endonuclease Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Type
        • 6.4.3.2.2. By Application
        • 6.4.3.2.3. By End Type
        • 6.4.3.2.4. By Source
        • 6.4.3.2.5. By Cleavage Specificity
        • 6.4.3.2.6. By End-User
    • 6.4.4. South Korea Restriction Endonuclease Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Type
        • 6.4.4.2.2. By Application
        • 6.4.4.2.3. By End Type
        • 6.4.4.2.4. By Source
        • 6.4.4.2.5. By Cleavage Specificity
        • 6.4.4.2.6. By End-User
    • 6.4.5. Singapore Restriction Endonuclease Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Type
        • 6.4.5.2.2. By Application
        • 6.4.5.2.3. By End Type
        • 6.4.5.2.4. By Source
        • 6.4.5.2.5. By Cleavage Specificity
        • 6.4.5.2.6. By End-User
    • 6.4.6. Australia Restriction Endonuclease Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Type
        • 6.4.6.2.2. By Application
        • 6.4.6.2.3. By End Type
        • 6.4.6.2.4. By Source
        • 6.4.6.2.5. By Cleavage Specificity
        • 6.4.6.2.6. By End-User

7. Europe Restriction Endonuclease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End Type
    • 7.2.4. By Source
    • 7.2.5. By Cleavage Specificity
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Restriction Endonuclease Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Type
        • 7.4.1.2.2. By Application
        • 7.4.1.2.3. By End Type
        • 7.4.1.2.4. By Source
        • 7.4.1.2.5. By Cleavage Specificity
        • 7.4.1.2.6. By End-User
    • 7.4.2. Germany Restriction Endonuclease Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Type
        • 7.4.2.2.2. By Application
        • 7.4.2.2.3. By End Type
        • 7.4.2.2.4. By Source
        • 7.4.2.2.5. By Cleavage Specificity
        • 7.4.2.2.6. By End-User
    • 7.4.3. United Kingdom Restriction Endonuclease Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Type
        • 7.4.3.2.2. By Application
        • 7.4.3.2.3. By End Type
        • 7.4.3.2.4. By Source
        • 7.4.3.2.5. By Cleavage Specificity
        • 7.4.3.2.6. By End-User
    • 7.4.4. Italy Restriction Endonuclease Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Type
        • 7.4.4.2.2. By Application
        • 7.4.4.2.3. By End Type
        • 7.4.4.2.4. By Source
        • 7.4.4.2.5. By Cleavage Specificity
        • 7.4.4.2.6. By End-User
    • 7.4.5. Spain Restriction Endonuclease Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Type
        • 7.4.5.2.2. By Application
        • 7.4.5.2.3. By End Type
        • 7.4.5.2.4. By Source
        • 7.4.5.2.5. By Cleavage Specificity
        • 7.4.5.2.6. By End-User

8. North America Restriction Endonuclease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Type
    • 8.2.4. By Source
    • 8.2.5. By Cleavage Specificity
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Restriction Endonuclease Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Type
        • 8.4.1.2.2. By Application
        • 8.4.1.2.3. By End Type
        • 8.4.1.2.4. By Source
        • 8.4.1.2.5. By Cleavage Specificity
        • 8.4.1.2.6. By End-User
    • 8.4.2. Mexico Restriction Endonuclease Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Type
        • 8.4.2.2.2. By Application
        • 8.4.2.2.3. By End Type
        • 8.4.2.2.4. By Source
        • 8.4.2.2.5. By Cleavage Specificity
        • 8.4.2.2.6. By End-User
    • 8.4.3. Canada Restriction Endonuclease Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Type
        • 8.4.3.2.2. By Application
        • 8.4.3.2.3. By End Type
        • 8.4.3.2.4. By Source
        • 8.4.3.2.5. By Cleavage Specificity
        • 8.4.3.2.6. By End-User

9. South America Restriction Endonuclease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End Type
    • 9.2.4. By Source
    • 9.2.5. By Cleavage Specificity
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Restriction Endonuclease Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Type
        • 9.4.1.2.2. By Application
        • 9.4.1.2.3. By End Type
        • 9.4.1.2.4. By Source
        • 9.4.1.2.5. By Cleavage Specificity
        • 9.4.1.2.6. By End-User
    • 9.4.2. Argentina Restriction Endonuclease Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Type
        • 9.4.2.2.2. By Application
        • 9.4.2.2.3. By End Type
        • 9.4.2.2.4. By Source
        • 9.4.2.2.5. By Cleavage Specificity
        • 9.4.2.2.6. By End-User
    • 9.4.3. Colombia Restriction Endonuclease Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Type
        • 9.4.3.2.2. By Application
        • 9.4.3.2.3. By End Type
        • 9.4.3.2.4. By Source
        • 9.4.3.2.5. By Cleavage Specificity
        • 9.4.3.2.6. By End-User

10. Middle East and Africa Restriction Endonuclease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End Type
    • 10.2.4. By Source
    • 10.2.5. By Cleavage Specificity
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Restriction Endonuclease Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Type
        • 10.4.1.2.2. By Application
        • 10.4.1.2.3. By End Type
        • 10.4.1.2.4. By Source
        • 10.4.1.2.5. By Cleavage Specificity
        • 10.4.1.2.6. By End-User
    • 10.4.2. Saudi Arabia Restriction Endonuclease Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Type
        • 10.4.2.2.2. By Application
        • 10.4.2.2.3. By End Type
        • 10.4.2.2.4. By Source
        • 10.4.2.2.5. By Cleavage Specificity
        • 10.4.2.2.6. By End-User
    • 10.4.3. UAE Restriction Endonuclease Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Type
        • 10.4.3.2.2. By Application
        • 10.4.3.2.3. By End Type
        • 10.4.3.2.4. By Source
        • 10.4.3.2.5. By Cleavage Specificity
        • 10.4.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. New England Biolabs
    • 13.2.2. Thermo Fisher Scientific
    • 13.2.3. Takara Bio
    • 13.2.4. Sigma-Aldrich
    • 13.2.5. Illumina
    • 13.2.6. Agilent Technologies
    • 13.2.7. Promega
    • 13.2.8. Jena Biosciences
    • 13.2.9. Genetix Biotech Asia Pvt. Ltd.
    • 13.2.10. Roche
    • 13.2.11. Merck
    • 13.2.12. Pfizer
    • 13.2.13. Amgen
    • 13.2.14. Vertex Pharmaceuticals
    • 13.2.15. BioMarin Pharmaceutical
    • 13.2.16. PerkinElmer
    • 13.2.17. Abcam
    • 13.2.18. Abbexa
    • 13.2.19. Sisco Research Laboratories Pvt Ltd
    • 13.2.20. Nippon Gene

14. Strategic Recommendations

15. About Us & Disclaimer

Back to Top
전화 문의
F A Q